These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 3539347)

  • 1. Low-dose oral contraceptives: progestin potency, androgenicity, and atherogenic potential.
    Ellis J
    Clin Ther; 1986; 8(6):607-18. PubMed ID: 3539347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metabolic impact of current estrogen-progestins and cardiovascular consequences].
    Gaspard U; Lambotte R
    Bull Mem Acad R Med Belg; 1991; 146(8-10):334-42; discussion 342-5. PubMed ID: 1815814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraceptives and the risk of cardiovascular disease.
    Med Lett Drugs Ther; 1983 Jul; 25(640):69-70. PubMed ID: 6865850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of the androgenicity of progestins in hormonal therapy in women.
    Linn ES
    Clin Ther; 1990; 12(5):447-55. PubMed ID: 2268868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral contraceptives and cardiovascular risk. Taking a safe course of action.
    Derman RJ
    Postgrad Med; 1990 Sep; 88(4):119-22. PubMed ID: 2204902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arteriosclerosis risk. The roles of oral contraceptives and postmenopausal estrogens.
    Knopp RH
    J Reprod Med; 1986 Sep; 31(9 Suppl):913-21. PubMed ID: 3772911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
    Gaspard U; Dubois M
    Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The formulation of oral contraceptives: does the amount of estrogen make any clinical difference?
    Speroff L
    Johns Hopkins Med J; 1982 May; 150(5):170-6. PubMed ID: 7043035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adverse effects of hormonal therapy.
    Bush TL
    Cardiol Clin; 1986 Feb; 4(1):145-52. PubMed ID: 3518931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oral contraceptives on circulating lipids and lipoproteins: maximizing benefit, minimizing risk.
    LaRosa JC
    Int J Fertil; 1989; 34 Suppl():71-84. PubMed ID: 2576264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How to choose an oral contraceptive in 1984].
    Rozenbaum H
    Contracept Fertil Sex (Paris); 1984 Nov; 12(11):1201-6. PubMed ID: 12266609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progestins and arterial disease].
    Rozenbaum H
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):344-52. PubMed ID: 12280205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lipids, lipoproteins, arterial accidents and oral contraceptives].
    Bakir R; Hilliquin P
    Contracept Fertil Sex (Paris); 1986 Jan; 14(1):81-7. PubMed ID: 12341243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OC practice guidelines: minimizing side effects.
    Darney PD
    Int J Fertil Womens Med; 1997; Suppl 1():158-69. PubMed ID: 9168375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid and lipoprotein changes in relation to oral contraception and hormonal replacement therapy.
    Burkman RT
    Fertil Steril; 1988 May; 49(5 Suppl 2):39S-50S. PubMed ID: 3282934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.